Clinical Trial Update: JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing JP-1366 20 mg with esomeprazole 40 mg in patients with erosive esophagitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis

Drugs mentioned

• Esomeprazole 40 mg (esomeprazole)
• JP-1366

Snippet

Sponsor: Onconic Therapeutics Inc. | Conditions: Erosive Esophagitis | Phase 3 | Status: COMPLETED